TY - CHAP
T1 - Hemoglobin vesicles as a molecular assembly. Characteristics of preparation process and performances as artificial oxygen carriers
AU - Sakai, Hiromi
AU - Sou, Keitaro
AU - Takeoka, Shinji
AU - Kobayashi, Koichi
AU - Tsuchida, Eishun
N1 - Funding Information:
This work was partly supported by Health Sciences Research Grants (Research on Regulatory Science), the Ministry of Health, Labour and Welfare, Japan. The authors gratefully acknowledge Professor Suematsu and Doctors H. Horinouchi, M. Watanabe, Y. Izumi and E. Ikeda (Keio University), Doctor H. Ikeda (Hokkaido Red Cross Blood Center, Sapporo), Doctor M. Takaori (Higashitakarazuka Satoh Hospital), Professor M. Intaglietta (University of California, San Diego), Professor W. T. Phillips (University of Texas, San Antonio), Doctor D. Erni (Inselspital University Hospital, Berne) and their active colleagues for the meaningful discussions and contributions to this research.
PY - 2006
Y1 - 2006
N2 - Liposome encapsulated hemoglobin is a long-sought goal in Japan, where the product is called hemoglobin vesicles (HbV), which distinguishes this product from the one developed primarily in the US, whose designation is liposome-encapsulated Hb (LEH). HbV is the result of a long series of studies in which the size of the vesicles, including the number of lipid layers, the surface composition and materials co-encapsulated have been optimized. HbV is produced by an extrusion process that has commercial potential, although at this time the product has not yet been produced in quantities sufficient for clinical trials. Sterilization of the hemoglobin, prior to encapsulation, is performed using heat, and antioxidants are co-encapsulated to retard hemoglobin oxidation. Oxygen affinity is regulated to any desired P50 by co-encapsulation of allosteric effectors, and this group has contributed important studies on the effect of different P 50 on oxygen delivery to tissues by HbV. The product is claimed to be stable when stored for up to 2 years. A commercial effort has been launched in Japan, and it is hoped that HbV could be in human clinical trials within the next few years. This chapter summarizes the characteristics of the preparation process of HbV based on the sciences of molecular assembly to induce their excellent performances.
AB - Liposome encapsulated hemoglobin is a long-sought goal in Japan, where the product is called hemoglobin vesicles (HbV), which distinguishes this product from the one developed primarily in the US, whose designation is liposome-encapsulated Hb (LEH). HbV is the result of a long series of studies in which the size of the vesicles, including the number of lipid layers, the surface composition and materials co-encapsulated have been optimized. HbV is produced by an extrusion process that has commercial potential, although at this time the product has not yet been produced in quantities sufficient for clinical trials. Sterilization of the hemoglobin, prior to encapsulation, is performed using heat, and antioxidants are co-encapsulated to retard hemoglobin oxidation. Oxygen affinity is regulated to any desired P50 by co-encapsulation of allosteric effectors, and this group has contributed important studies on the effect of different P 50 on oxygen delivery to tissues by HbV. The product is claimed to be stable when stored for up to 2 years. A commercial effort has been launched in Japan, and it is hoped that HbV could be in human clinical trials within the next few years. This chapter summarizes the characteristics of the preparation process of HbV based on the sciences of molecular assembly to induce their excellent performances.
UR - http://www.scopus.com/inward/record.url?scp=33746453597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746453597&partnerID=8YFLogxK
U2 - 10.1016/B978-012759760-7/50055-X
DO - 10.1016/B978-012759760-7/50055-X
M3 - Chapter
AN - SCOPUS:33746453597
SN - 9780127597607
SP - 514
EP - 522
BT - Blood Substitutes
PB - Elsevier Ltd
ER -